Exploring the role of novel medical therapies for aggressive pituitary tumors: A review of the literature -"Are We There Yet?"
Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized by resistance to medical treatment and multiple recurrences despite standard therapies, including surgery, radiotherapy, and chemotherapy. They are associated with increased morbidity and mortality, particularly pituitary carcinomas, which have mortality rates of up to 66% at 1 year after diagnosis. Novel targeted therapies under investigation include mammalian target of rapamycin (mTOR), tyrosine kinase, and vascular endothelial growth factor (VEGF) inhibitors. More recently, immune checkpoint inhibitors have been proposed as a potential treatment option for pituitary tumors. An increased understanding of the molecular pathogenesis of aggressive pituitary tumors is required to identify potential biomarkers and therapeutic targets. This review discusses novel approaches to the management of aggressive pituitary tumors and the role of molecular profiling.
|ISBN||2072-6694 (Print) 2072-6694 (Linking)|
|Authors||Lamb, L. S.; Sim, H. W.; McCormack, A. I.|
|Responsible Garvan Author||Dr Ann McCormack|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/32012988|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/15331|